[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Biomarkers in the Central Nervous System

March 2019 | 150 pages | ID: BEAB56B1408EN
GlobalData

US$ 7,995.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Biomarkers in the Central Nervous System

SUMMARY

Biomarkers in CNS are expected to be an area that will witness strong growth in the future due to factors such as deeper understanding of the underlying disease pathology, advancements in technologies, and potential of these biomarkers that can contribute to targeted therapy. Biomarkers in CNS targeting a number of neurology indications are being developed; however, the most common ones are Alzheimer’s disease (AD), Schizophrenia and Multiple Sclerosis (MS).

'Biomarkers in the Central Nervous System', report provides an overview of current clinical and product development trends for Biomarkers in CNS within the 8MM (France, Germany, Italy, Spain, UK, US, Japan, China), including analysis of the most common targets and molecule types that are being evaluated among the current biomarkers, focus on product development in indications such as AD, Schizophrenia MS, and unmet needs within biomarkers in CNS.

SCOPE
  • Quotes from 6 key opinion leaders (3 US, 1 EU, 2 Japan) and 2 payers (1 US and 1 UK)
  • Summary of biomarkers product definitions and classifications
  • Overview of common targets and molecule types among current biomarkers, with focus on product development in AD, Schizophrenia and MS
  • Trends in ongoing clinical trials in biomarkers in CNS based on sponsor type, and phase of development
  • Call-outs of key information and details
  • Insight from GlobalData’s specialist neurology analysts.
REASONS TO BUY
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global Glaucoma market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Glaucoma market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
1. PREFACE

1.1 Abbreviations
1.2 Related Reports

2. EXECUTIVE SUMMARY

2.1 Key Findings
2.2 KOL and Payer Insights

3. INTRODUCTION AND CLASSIFICATION OF BIOMARKERS

3.1 Definition of Biomarker
3.2 Type of Biomarkers
3.3 Biomarkers in CNS
3.4 KOL Perspectives

4. BIOMARKERS SUPPORT TECHNOLOGIES IN CNS

4.1 Overview
4.2 Neuroimaging, Genomics and Proteomics
4.3 Epigenetic, Metabolomics and Transcriptomics
4.4 Lipidomics and Immune system
4.5 Biomarkers Diagnosis Methods in CNS
4.6 KOL Perspectives

5. ASSESSMENT OF CLINICAL TRIALS INVOLVING BIOMARKERS IN THE 8MM

5.1 Pipeline Overview 8MM
5.2 Biomarkers Trials - Top Indications in CNS in the 8MM
5.3 Clinical Trials - Leading Industry Sponsors in the 8MM

6. INDICATION-SPECIFIC OVERVIEW: ALZHEIMER’S DISEASE

6.1 Overview
6.2 Epidemiology
6.3 Global Statistic Biomarkers in AD
6.4 Biomarkers in AD
6.5 Neuroimaging in AD
6.6 Amyloid Biomarkers
6.7 AD Biomarkers Products
6.8 CSF Amyloid Based Tests
6.9 Blood Tests
6.10 Tau Biomarkers
6.11 Genetic Biomarkers
6.12 Unmet needs and Challenges in AD Biomarkers
6.13 KOL Perspectives

7. INDICATION-SPECIFIC OVERVIEW: SCHIZOPHRENIA

7.1 Overview
7.2 Epidemiology
7.3 Global Statistic Biomarkers in Schizophrenia
7.4 Biomarkers in Schizophrenia
7.5 Neuroimaging in Schizophrenia
7.6 Genetic and Epigenetic Biomarkers in Schizophrenia
7.7 Protein Biomarkers in Schizophrenia
7.8 Metabolic and Other Biomarkers in Schizophrenia
7.9 Unmet needs and Challenges in Schizophrenia Biomarkers
7.10 KOL Perspectives

8. INDICATION-SPECIFIC OVERVIEW: MULTIPLE SCLEROSIS

8.1 Overview
8.2 Epidemiology
8.3 Global Statistic Biomarkers in MS
8.4 Biomarkers in MS
8.5 Diagnostic Biomarkers in MS -Neuroimaging
8.6 Diagnostic Biomarkers in MS -Intrathecal Immunoglobulin G Synthesis
8.7 Genetic Biomarkers in MS
8.8 Biomarkers to Guide Choice of Therapy
8.9 Promising Biomarkers in MS - Neurofilament Light Chain
8.10 Biomarkers in MS - Glial Pathology
8.11 Unmet needs and Challenges in MS Biomarkers
8.12 KOL Perspectives

9. MARKET OPPORTUNITIES

9.1 Overview
9.2 Market Drivers
9.3 Market Barriers
9.4 Unmet Needs
9.5 Experts Perspectives

10. MARKET ACCESS

10.1 Overview
10.2 Regulation and Reimbursement in the US
  10.2.1 Payer Perspective
10.3 Regulation and Reimbursement in the EU
  10.3.1 Payer Perspective
10.4 Regulation and Reimbursement in Japan
  10.4.1 KOL Perspective
10.5 Regulation and Reimbursement in China

11. MARKET OUTLOOK

11.1 Expert Perspectives

12. APPENDIX

12.1 Sources
12.2 Methodology
12.3 Primary Research
12.4 About the Authors
12.5 About GlobalData
12.6 Contact Us

COMPANIES MENTIONED

Sanofi
InviCRO
Lunbeck
Eisai
F. Hoffmann- La Roche
J&J
Biogen
GSK
Eli Lilly
Brystol-Myers Squibb
Regenera Pharma
Araclon Biotech
EIP Pharma
Sunnybrook Health Sciences Centre
AstraZeneca
Boehringer Ingelheim
Les Laboratoires Servier
GE Healthcare
Piramal
Forest Laboratories
Alkermes
Sunovion Pharmaceuticals
Intra-Cellular Therapies
GW Pharmaceuticals
Novartis
Merck
Teva
Genzyme
AbbVie
Pfizer


More Publications